Synaptogenix IncNASDAQ:SNPX
- LAST PRICE2.7100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.3000/ 8
- Ask / Lots2.9000/ 1
- Open / Previous Close--- / 2.7100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNPX |
|---|---|---|
| 09:32 ET | 577 | 2.65 |
| 11:21 ET | 335 | 2.73 |
| 11:23 ET | 4320 | 2.74 |
| 11:32 ET | 324 | 2.6682 |
| 11:56 ET | 6230 | 2.8201 |
| 11:57 ET | 100 | 2.81 |
| 12:32 ET | 900 | 2.71 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Synaptogenix Inc | 3.5M | -0.4x | --- |
Bio Path Holdings Inc | 3.5M | -0.1x | --- |
Artelo Biosciences Inc | 3.6M | -0.4x | --- |
ProtoKinetix Inc | 3.5M | -8.8x | --- |
Theriva Biologics Inc | 3.6M | -0.1x | --- |
Qualigen Therapeutics Inc | 3.6M | -0.1x | --- |
Company Information
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.
Contact Information
- Headquarters
- 1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK, NY, United States 10036
- Phone
- 973-242-0005
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joshua Silverman
- President, Chief Scientific Officer, Director
- Daniel Alkon
- Chief Executive Officer, Director
- Alan Tuchman
- Independent Vice Chairman of the Board
- William Singer
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Robert Weinstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-7.63 |
Book Value | $26.55 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
